Bioceltix S.A.

Warsaw Stock Exchange BCX.WA

Bioceltix S.A. Price to Sales Ratio (P/S) on February 03, 2025

Bioceltix S.A. Price to Sales Ratio (P/S) is NA on February 03, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Bioceltix S.A. 52-week high Price to Sales Ratio (P/S) is NA on February 03, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • Bioceltix S.A. 52-week low Price to Sales Ratio (P/S) is NA on February 03, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • Bioceltix S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
SV Wall Street
Warsaw Stock Exchange: BCX.WA

Bioceltix S.A.

CEO Mr. Lukasz Bzdzion
IPO Date Nov. 8, 2021
Location Poland
Headquarters Building III
Employees 28
Sector Healthcare
Industries
Biotechnology Pet Food Pharmaceuticals
Description

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.

StockViz Staff

February 6, 2025

Any question? Send us an email